These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16258435)

  • 1. Regulation of c-Raf-1: therapeutic implications.
    Beeram M; Patnaik A; Rowinsky EK
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):476-81. PubMed ID: 16258435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raf pathway inhibitors in oncology.
    Bollag G; Freeman S; Lyons JF; Post LE
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1436-41. PubMed ID: 14763129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
    Kramer BW; Götz R; Rapp UR
    BMC Cancer; 2004 Jun; 4():24. PubMed ID: 15171791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
    Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the RAF-MEK-ERK pathway in cancer therapy.
    Montagut C; Settleman J
    Cancer Lett; 2009 Oct; 283(2):125-34. PubMed ID: 19217204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is B-Raf a good therapeutic target for melanoma and other malignancies?
    Madhunapantula SV; Robertson GP
    Cancer Res; 2008 Jan; 68(1):5-8. PubMed ID: 18172288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-Raf kinase inhibitors for cancer treatment.
    Li N; Batt D; Warmuth M
    Curr Opin Investig Drugs; 2007 Jun; 8(6):452-6. PubMed ID: 17621874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raf kinase inhibitors in oncology.
    Strumberg D; Seeber S
    Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
    Kogut MH; Genovese KJ; He H
    Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second nature: biological functions of the Raf-1 "kinase".
    Baccarini M
    FEBS Lett; 2005 Jun; 579(15):3271-7. PubMed ID: 15943972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.
    McCubrey JA; Milella M; Tafuri A; Martelli AM; Lunghi P; Bonati A; Cervello M; Lee JT; Steelman LS
    Curr Opin Investig Drugs; 2008 Jun; 9(6):614-30. PubMed ID: 18516761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
    Friday BB; Adjei AA
    Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.